Deriving reference values and utilities for the QoL-AGHDA in adult GHD.
BACKGROUND
Quality of life (QoL) measures are important in growth hormone (GH) deficiency (GHD) in adults. Ideally, for use in health economics, QoL should be expressed in utilities. The aim of this study was to obtain reference values and utilities for QoL of GHD in adults in Belgium and the Netherlands.


METHODS
The study was conducted in three stages: (1) The Quality of Life-Assessment for Growth Hormone Deficiency in Adults (QoL-AGHDA) and the EQ-5D were administered in a representative sample of 6,875 individuals from the Belgian and 1,400 individuals from the general Dutch population. The EQ-5D(index) can be used to estimate utilities. Using a regression, utilities were predicted from the QoL-AGHDA. (2) QoL-AGHDA scores were obtained from 299 Belgian and 234 Dutch adult patients with GHD and no GH replacement. These scores were converted to utilities and compared the burden of disease with other patient groups. (3) To test the criterion validity, the 'standard' EQ-5D(index) was used in a subsample of 64 Dutch GHD patients and compared with the predicted utilities.


RESULTS
We obtained data from 1,026 Belgian (response rate = 15%) and 1,038 Dutch respondents (response rate = 74%). The Belgian mean QoL-AGHDA value was 6.95 (90% range = 14.00), and the Dutch mean was 5.48 (range = 13.00). The R (2) of the regression model to predict the EQ-5D(index) was 0.360 (Belgium) and 0.482 (the Netherlands). We demonstrated a considerable burden of disease in GHD patients, comparable to patients with hypertension or with type II diabetes. The criterion validity was 0.407 (intraclass correlation, ICC).


CONCLUSIONS
Interventions in GHD can now be evaluated more validly in Belgium and the Netherlands.
Busschbach
J J V
JJ
Medical Psychology and Psychotherapy, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. J.vanbusschbach@erasmusmc.nl
Wolffenbuttel
B H R
BH
Annemans
L
L
Meerding
W J
WJ
Kołtowska-Häggström
M
M
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001530:Belgium; D005260:Female; D013006:Growth Hormone / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012016:Reference Values; D012737:Sex Factors; D011795:Surveys and Questionnaires / Q000592:standards*; D055815:Young Adult
D013006:Growth Hormone
Med Care. 2009 Jun;47(6):634-41
19433996
BMJ. 1998 Mar 7;316(7133):736-41
9529408
Endocr Rev. 2006 May;27(3):287-317
16543384
Eur J Endocrinol. 2006 Jul;155(1):109-19
16793956
Qual Life Res. 1999 Jun;8(4):373-83
10472170
Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):90-102
17957812
Neurology. 2002 Jul 9;59(1):103-8
12105315
Clin Endocrinol (Oxf). 2008 Jan;68(1):122-9
17803700
J Health Econ. 1999 Oct;18(5):551-71
10621364
Ann Rheum Dis. 2007 Jun;66(6):771-7
17213254
Value Health. 2007 Jan-Feb;10(1):73-81
17261118
Qual Life Res. 2003 Jun;12(4):363-71
12797709
Diabetologia. 2002 Jul;45(7):S18-22
12136407
Health Policy. 1992 Oct;22(3):307-19
10122730
Arthritis Rheum. 2007 Aug 15;57(6):1043-9
17665466
Clin Endocrinol (Oxf). 2000 Feb;52(2):143-52
10671940
Qual Life Res. 2000;9(6):591-601
11236850
Qual Life Res. 2001;10(7):621-35
11822795
Soc Sci Med. 2006 Nov;63(9):2367-80
16884840
Health Econ. 2006 Oct;15(10):1121-32
16786549
Pharmacoeconomics. 2004;22(17):1097-107
15612829